Todd Sone

Ultima Genomics is unleashing the power of genomics at scale. Our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.

aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives. We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality. Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.

Ultima Genomics is unleashing the power of genomics at scale. Our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.

Claris Ltd. (Claris) is a holding company established with a long-term objective of diversifying to multiple businesses, driven by the spirit of innovation & desire to make sustainable impact. Powered by our experience in building large scale global healthcare businesses from scratch, efficiently & quickly, Claris has pivoted itself for new growth & opportunity through investments & management interest in the fields of Clean Energy, Venture Capital & Incubators. Our genesis dates to 1999 with Claris Lifesciences, a healthcare company with focus on infusions and specialty injectables. At its peak, the infusions business, had more than 50% market share in the IV fluids segment. In the Injectables space, Claris was one of the largest pure-play sterile generic injectable companies in India, with approvals from the most stringent regulatory bodies in the world like US FDA, MHRA (UK) and TGA (Australia), among others. In a span of two decades, the company created nearly billion-dollar valuation, established world-class integrated business model, introduced over 130 products, built presence in over 100 countries, had a team of over 4,000, and was listed on the Bombay Stock Exchange. Claris exited healthcare in 2017, after sale of injectables business to Baxter and infusions business to Otsuka and Mitsui. At the helm since 2008, Vice Chairman and MD Arjun Handa brought accelerated growth that saw Claris leverage cutting-edge manufacturing capabilities. As a former national-level football player the lessons Arjun learnt on the pitch, from team spirit to perseverance, have reflected in his ability to strategize, inspire and lead. Our commitment to a people-centric culture has helped Claris win ‘India’s Best Companies To Work For’ award, 8 years in a row. Parallel to striving for excellence, Claris serves as a socially responsible organization by supporting and encouraging various social causes in the area of sports and fitness, business and entrepreneurship, art and culture.

Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. Signet focuses primarily on the pharmaceutical and medical technology sectors. Signet is an active investor and partners closely with management teams to support growth and build successful businesses. During our 25-year history, we have developed a strong reputation and track record of successful healthcare investments. We have raised funds with total capital commitments of over $600 million and have invested in more than 55 companies.

Dear Dental Professionals, At Oral Science, our mission is to create optimal and more predictable clinical outcomes by creating synergies between the most efficient and evidence-based in-office treatments and innovative home-care solutions for the treatment of: • High Risk Caries • Oral Lesions • Periodontitis • Xerostomia • Tooth Sensitivity • Oral Lesions We look forward to partnering and collaborating with you towards excellence. The Oral Science Team